There is only one clinical trial for lixisenatide in PD, assessing its efficacy in slowing motor disability progression in early-stage patients over 12 months, followed by a 2-month washout period
PDRN (polydeoxyribonucleotide) is the most commonly recommended gentler alternative to copper peptides
Sirtuin modulation Modulating sirtuin activity by targeting NAD + -dependent deacylation may hold therapeutic potential for impacting mitochondrial homeostasis and other cellular pathways related to aging and disease
Because of this effect on bone, the FDA recommends that GnRH agonists should only be used for the short-term treatment of fibroids less than six months (Doherty 2014
3 Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Anyone considering the medication should talk to their doctor to see if it is right for them